Accelerate Diagnostics Stock Analysis
| AXDX Stock | USD 0.04 0.02 164.90% |
Accelerate Diagnostics is undervalued with Real Value of 0.4 and Target Price of 1.5. The main objective of Accelerate Diagnostics stock analysis is to determine its intrinsic value, which is an estimate of what Accelerate Diagnostics is worth, separate from its market price. There are two main types of Accelerate Diagnostics' stock analysis: fundamental analysis and technical analysis.
The Accelerate Diagnostics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Accelerate Diagnostics is usually not traded on Christmas Day, New Year 's Day, National Mourning Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day. Accelerate Stock trading window is adjusted to America/New York timezone.
Accelerate | Build AI portfolio with Accelerate Stock |
Accelerate Stock Analysis Notes
About 38.0% of the company shares are held by company insiders. The company recorded a loss per share of 2.15. Accelerate Diagnostics had not issued any dividends in recent years. The entity had 1:10 split on the 12th of July 2023. Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona. Accelerate Diagnosti operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 220 people. For more info on Accelerate Diagnostics please contact Jack Phillips at 520 365 3100 or go to https://acceleratediagnostics.com.Accelerate Diagnostics Investment Alerts
| Accelerate Diagnostics is not yet fully synchronised with the market data | |
| Accelerate Diagnostics generated a negative expected return over the last 90 days | |
| Accelerate Diagnostics has high historical volatility and very poor performance | |
| Accelerate Diagnostics has some characteristics of a very speculative penny stock | |
| Accelerate Diagnostics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 11.7 M. Net Loss for the year was (50.05 M) with profit before overhead, payroll, taxes, and interest of 2.7 M. | |
| Accelerate Diagnostics currently holds about 36.77 M in cash with (24.19 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.45, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Accelerate Diagnostics has a frail financial position based on the latest SEC disclosures | |
| Roughly 38.0% of the company shares are held by company insiders | |
| Latest headline from businesswire.com: The Next Step in Jack in the Boxs Innovative Drink Lineage New SOUR PATCH KIDS Watermelon Beverages |
Accelerate Diagnostics Upcoming and Recent Events
Earnings reports are used by Accelerate Diagnostics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period..
| 3rd of April 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 3rd of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Accelerate Largest EPS Surprises
Earnings surprises can significantly impact Accelerate Diagnostics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
1998-05-20 | 1998-03-31 | 0.12 | 0.14 | 0.02 | 16 | ||
1997-03-17 | 1996-12-31 | 0.03 | 0.01 | -0.02 | 66 | ||
2023-05-11 | 2023-03-31 | -0.14 | -0.17 | -0.03 | 21 |
Accelerate Stock Institutional Investors
| Shares | Susquehanna International Group, Llp | 2024-12-31 | 29.7 K | Citadel Advisors Llc | 2025-03-31 | 23.5 K | State Street Corp | 2025-03-31 | 20.4 K | Ironwood Wealth Management, Llc | 2025-03-31 | 20.3 K | Two Sigma Securities, Llc | 2025-03-31 | 18.4 K | Northern Trust Corp | 2025-03-31 | 17 K | Tudor Investment Corp Et Al | 2025-03-31 | 14.1 K | Tejara Capital Ltd | 2025-03-31 | 13.1 K | Hanson Mcclain Inc | 2025-03-31 | 10.4 K | Armistice Capital, Llc | 2025-03-31 | 1.9 M | Hovey Youngman Associates Inc | 2025-03-31 | 853 K |
Accelerate Market Capitalization
The company currently falls under 'Nano-Cap' category with a current market capitalization of 859.92 K.Accelerate Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.75) | (1.66) | |
| Return On Capital Employed | 13.35 | 14.02 | |
| Return On Assets | (1.75) | (1.66) | |
| Return On Equity | 0.89 | 0.45 |
Management Efficiency
Accelerate Diagnostics has return on total asset (ROA) of (0.7366) % which means that it has lost $0.7366 on every $100 spent on assets. This is way below average. Accelerate Diagnostics' management efficiency ratios could be used to measure how well Accelerate Diagnostics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to rise to 14.02 in 2025, despite the fact that Return On Tangible Assets are likely to grow to (1.66). At this time, Accelerate Diagnostics' Total Assets are fairly stable compared to the past year. Non Currrent Assets Other is likely to rise to about 696.7 K in 2025, whereas Non Current Assets Total are likely to drop slightly above 5.4 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (2.40) | (2.28) | |
| Tangible Book Value Per Share | (2.40) | (2.28) | |
| Enterprise Value Over EBITDA | (2.37) | (2.48) | |
| Price Book Value Ratio | (0.50) | (0.47) | |
| Enterprise Value Multiple | (2.37) | (2.48) | |
| Price Fair Value | (0.50) | (0.47) | |
| Enterprise Value | 10.1 M | 9.6 M |
Management at Accelerate Diagnostics focuses on leveraging technology and optimizing operations. We evaluate the impact of these focuses on the company's financial health and stock performance.
Accelerate Diagnostics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Accelerate Diagnostics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Accelerate Diagnostics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Accelerate Diagnostics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Accelerate Diagnostics Outstanding Bonds
Accelerate Diagnostics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Accelerate Diagnostics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Accelerate bonds can be classified according to their maturity, which is the date when Accelerate Diagnostics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Accelerate Diagnostics Predictive Daily Indicators
Accelerate Diagnostics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Accelerate Diagnostics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 0.75 | |||
| Daily Balance Of Power | 0.6785 | |||
| Rate Of Daily Change | 2.65 | |||
| Day Median Price | 0.0307 | |||
| Day Typical Price | 0.0338 | |||
| Market Facilitation Index | 0.0367 | |||
| Price Action Indicator | 0.0218 | |||
| Period Momentum Indicator | 0.0249 | |||
| Relative Strength Index | 32.57 |
About Accelerate Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Accelerate Diagnostics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Accelerate shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Accelerate Diagnostics. By using and applying Accelerate Stock analysis, traders can create a robust methodology for identifying Accelerate entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (4.28) | (4.50) | |
| Operating Profit Margin | (3.02) | (3.17) | |
| Net Loss | (4.28) | (4.49) | |
| Gross Profit Margin | 0.23 | 0.22 |
Current Accelerate Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Accelerate analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Accelerate analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 1.5 | Strong Buy | 1 | Odds |
Most Accelerate analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Accelerate stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Accelerate Diagnostics, talking to its executives and customers, or listening to Accelerate conference calls.
Accelerate Stock Analysis Indicators
Accelerate Diagnostics stock analysis indicators help investors evaluate how Accelerate Diagnostics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Accelerate Diagnostics shares will generate the highest return on investment. By understating and applying Accelerate Diagnostics stock analysis, traders can identify Accelerate Diagnostics position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 12.1 M | |
| Long Term Debt | 46.8 M | |
| Common Stock Shares Outstanding | 23.3 M | |
| Total Stockholder Equity | -56 M | |
| Tax Provision | -66 K | |
| Property Plant And Equipment Net | 5.8 M | |
| Cash And Short Term Investments | 16.3 M | |
| Cash | 15.1 M | |
| Accounts Payable | 4.8 M | |
| Net Debt | 51.5 M | |
| 50 Day M A | 0.5338 | |
| Total Current Liabilities | 31.2 M | |
| Other Operating Expenses | 47 M | |
| Non Current Assets Total | 6.3 M | |
| Non Currrent Assets Other | 500 K | |
| Stock Based Compensation | 4.4 M |
Additional Tools for Accelerate Stock Analysis
When running Accelerate Diagnostics' price analysis, check to measure Accelerate Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Accelerate Diagnostics is operating at the current time. Most of Accelerate Diagnostics' value examination focuses on studying past and present price action to predict the probability of Accelerate Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Accelerate Diagnostics' price. Additionally, you may evaluate how the addition of Accelerate Diagnostics to your portfolios can decrease your overall portfolio volatility.